利用贝叶斯加性回归树探索与短期反应和长期结局相关的敏感生物标志物
该研究提出一种探索性两阶段亚组分析方法,利用贝叶斯加性回归树(BART)基于短期基线后生物标志物反应推导预测性条件治疗效应(PCTE),并通过模拟研究和一项局部晚期或转移性乳腺癌随机临床试验数据验证短期反应对长期结局的预测价值。
要点
- BART模型可基于短期生物标志物反应推导预测性条件治疗效应。
- 按PCTE构建患者亚组可识别对治疗敏感的亚群。
- 方法在乳腺癌临床试验数据中展示了短期反应的预测价值。
核心结论
- 短期基线后生物标志物反应对长期结局具有预测价值,所提统计方法可识别预期从新治疗中获益的患者。
研究设计与样本
- 提出探索性两阶段亚组分析方法,使用贝叶斯加性回归树(BART)进行反事实建模,并通过广泛模拟研究考察方法操作特性,最后应用于一项局部晚期或转移性乳腺癌随机临床试验数据。
主要发现
- 模拟研究考察了所提方法的操作特性;在乳腺癌临床试验数据应用中,结果支持短期反应的预测价值。
临床怎么用
- 早期基线后生物标志物反应可作为医生决定是否继续治疗的辅助参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Identifying good predictive baseline covariates to optimize the target population for a new treatment is an important aim in precision medicine. Early post-baseline biomarker responses may serve as a supportive guide for physicians to decide whether to continue a treatment. We propose an exploratory two-stage subgroup analysis method as a statistical tool to investigate the predictive value of such a short-term response for the benefit of a new treatment in terms of long-term outcomes. We use a flexible probability model, Bayesian additive regression trees (BART), to derive predictive conditional treatment effects (PCTE) based on a short-term post-baseline biomarker response using counterfactual modeling of responses to new and standard treatments for each patient. Constructing patient subgroups according to the PCTE, we analyze an observed long-term outcome to identify a sensitive subpopulation. We carry out extensive simulation studies to examine the operating characteristics of the proposed method. For illustration, we apply the proposed method to data from a randomized clinical trial in patients with locally advanced or metastatic breast cancer. These findings support the predictive value of short-term responses and provide a statistical approach for identifying patients expected to benefit from a new treatment in terms of a long-term outcome.
引用
- Yao Z, Morita S. Exploring Sensitive Biomarkers Associated With Short-Term Responses and Long-Term Outcomes Using Bayesian Additive Regression Trees. Stat Med. 2026. PMID: 42210570. doi:10.1002/sim.70620
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。